Gerresheimer Growth


Growth accelerated significantly

The financial year 2021 is clear evidence of the effectiveness and the success of our strategy. The momentum in the implementation of formula G continues unabated. Together as One Gerresheimer, we are leveraging synergies, innovating across divisional boundaries, and accelerating growth. The key growth drivers defined at the beginning of the financial year 2021 developed as planned, supported by global megatrends.

Focus on High Value Solutions and Gx Biological Solutions

Organic revenue growth in 2021 was driven by our High Value Solutions, in particular by Gx Biological Solutions. One of the structural growth trends within the pharma industry is the development of biological drugs, which have become increasingly important in recent years. This trend is expected to continue in the years ahead.

Although the market for chemical drugs will remain strong, we see even greater growth potential for biological drugs and their fields of application. With the biologicals sector will offering significant growth opportunities, we will make sure that Gerresheimer — with its uniquely broad product portfolio — serves biotech companies with the right product solutions, from standardized pharma products and customized product solutions to smart and digital devices.

Our Gx Biological Solutions unit offers enhanced services for pharma packaging solutions serving the needs of small, medium, and large biotech companies. The team is very successful, as underpinned by impressive growth rates. The main contributors to both revenue and margin acceleration in biologics in the years ahead will be RTF syringes and our Elite Glass vials, as well as ready-to-fill vials.

Read more about our RTF syringes

Read more about our RTF vials

Global Network and Competencies

We develop the right solutions for our customers across divisional boundaries. To this end, we are increasingly linking and connecting our competencies and growing even closer together as a team.

In 2021, we focused our investments on expanding capacities for injectable drug delivery solutions, including in particular glass vials and syringes. We are on our way to becoming the largest producer of injection vials in the world. In the course of this, we have made a clear decision to expand our site in Wertheim. At the same time, we significantly increased capacity at our existing vial plants worldwide.

In addition, we also continued to invest in our global presence. Besides the above-mentioned investments, we expanded our offerings in emerging markets. We made significant investments in capacities in China and expanded our capacities for glass and plastic solutions. The same applies to India and Brazil. This move strengthens our position as a global solutions provider and enables us to offer customized solutions around the world.

Contract Manufacturing

Another important focus of our investment plans is our contract manufacturing business. Due to the significant increase in orders received from existing and new customers, we are significantly expanding our production capacities, particularly in Europe.

A significant order is the production of a well-known auto injector. The production is currently ramping up and we are ready for production start in fiscal year 2022. This order will make a significant contribution to growth in the next financial year.

Read more about Contract Manufacturing

Further stories

Contact us!

Investor Relations
Contact: Investor Relations